GORMONAL'NAYa TERAPIYa RAKA PREDSTATEL'NOY ZhELEZY


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Currently, according to international expert opinion, hormone therapy (HT) is standard of treatment for patients with disseminated prostate cancer (PC). The article discusses the administration of HT for localized and locally advanced prostate cancer, including the feasibility of HT prior to surgery and radiation therapy. The article also discusses some aspects of the use of hormonal therapy in metastatic prostate cancer: a comparison of immediate and delayed HT, applicability of adding of anti-androgen therapy to castration therapy, the potentials for the use of intermittent hormonal therapy regimen.

全文:

受限制的访问

作者简介

V. Chernyaev

参考

  1. Walsh P.C. Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am;2(1):125-40.
  2. Huggins C., Stevens R.E. Jr., Hodges C.V. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-23.
  3. McLeod D.G. Hormonal therapy: historical perspective to future directions. Urology 2003;61(2 Suppl 1):3-7.
  4. Perez-Marreno R., Chu F.M., Gleason D., et al. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24:1902-14.
  5. Trachtenberg J. A phase 3, multicenter, open label, randomized study of abarelix versus leuprorelin plus daily antiandrogen in men with prostate cancer. J Urol 2002;167(4):1670-74.
  6. Moffat L.E. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990;18(Suppl 3):26-7.
  7. Черняев В.А., Матвеев В.Б., Волкова М.И. и др. Факторы прогноза биохимического рецидива локализованного и местнораспространенного рака простаты после радикальной простатэктомии // Онкоурология. 2012. № 4. С. 58-64.
  8. McLeod D.G., Iversen P., See W.A., et al. Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97(2):247-54.
  9. Shelley M.D., Kumar S., Wilt T., еt al. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35(1):9-17.
  10. Zelefsky M.J., Pei X., Chou J.F., et al. Dose escalation for prostate cancer radiotherapy: predictors of long term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 2011;60(6):1133-39.
  11. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26(15):2497-504.
  12. Lawton C.A., Winter K., Grignon D., et al. Androgen suppression plus radiation versus radiation alone for patients with D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on a national prospective randomized trial, RTOG 85-31. J Clin Oncol 2005;23(4):800-7.
  13. Seidenfeld J., Samson D.J., Aronson N. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ). 1999 May;(4):i-x,1-246,I1-36, passim.
  14. Studer U.E., Collette L., Whelan P., et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2011;53:941-49.
  15. Klotz L., Schellhammer P. Combined androgen blockade: the case for bicalutamide. Clin Prostate Cancer 2005;3(4):215-19.
  16. Calais da Silva F.E., Bono A.V., Whelan P., et al. ntermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009;55(6):1269-77.
  17. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 2007;99(Suppl 1):19-22; discussion 23-4.
  18. Crook J.M., O'Callaghan C.J., Duncan G. et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367(10):895-903.
  19. Scholz M.C., Jennrich R.I., Strum S.B., et al. Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period. J Urol 2006;175(5): 1673-78.
  20. Buchan N.C., Goldenberg S.L. Intermittent versus continuous androgen suppression therapy: do we have consensus yet? Curr Oncol 2010;17(Suppl 2):S45-48.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013